Remove

Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-03-02
First Named Inventor Sang		Kyun CHO
Art Unit		
Examiner Name		
Attorney Docket Numb	or	

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines whe Relevant Passages or Rele Figures Appear			
	1	5863590		1999-0	1-26	Tetra Laval Ho S.A.					
	2	5955134		1999-0	9-21	Fuji Oil Compi	any, Limited				
	3 6316043 B1 2001-11-13 Haruo Tsumura et al.										
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	of cited Document		Releva	,Columns,Lin ant Passage: s Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d buttor	1. Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial* Cite No Number Country		y Code ² Kind Code ⁴		Publication Date	Name of Patente Applicant of cited Document		Pages,Colur where Relev Passages or Figures App	ant Relevant	Ts		
	1	03045170	wo		A1	2003-06-05	Gandhi, N., R., et a	al.			
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		

U.S.PATENTS

INFORMATION DISCLOSUR STATEMENT BY APPLICAN'						
	INFORMATION DIGGI COURT	Filing Date		2006-03-02		
		First Named Inventor Sang		Kyun CHO		
	(Not for submission under 37 CFR 1.99)	Art Unit				
	(Not for Submission ander or or it 1.50)	Examiner Name				
		Attorney Docket Numb	er			
	NON-	PATENT LITERATURE	DOCL	UMENTS	Remove	_

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Annlication Number

publisher, city and/or country where published.

Evaminer Cite

English language translation is attached.

Initials* No.

1								
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a								

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patient Documents at year USPTO_GOD or MPEP 501.04. Enter office that issued the document, by the hor-letter code (WIPO Standard ST.3). For Japanese patient document, be included not the operand that inspire of the Emparer may proced the serial number of the patient codement. Affine document by the proporates problem as included on the Source under WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where WIPO Standard ST.3 if grossite. Explaint also place accurate where we will be accurate the WIPO Standard ST.3 if grossite in the whole accurate which will be accurate the WIPO Standard ST.3 if grossite in the whole accurate which will be accurate the whole accurate the whole accurate which will be accurate the whole accur

INFORMATION DISCLOSURE	Application Number			
	Filing Date		2006-03-02	
	First Named Inventor	Sang	Kyun CHO	
	(Not for submission under 37 CFR 1.99)	Art Unit		
		Examiner Name		
		Attorney Docket Numb	er	

CERTIFICATION STATEMENT

Please see 37			

√ None

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.SC. 122 and 37 CFR 1.41. This collection is estimated to set incur to complete, including gathering, preparing and submitting the complete of the complete of the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commence, P. 0. Stot 1450, Alexandric, N.2.2311-1450, D. ORT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1459, Alexandric, N.2.2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.